Episode Details

Back to Episodes

Pharmaceutical Executive Daily: Foghorn Therapeutics & Eli Lilly Discontinue Development of FHD-909

Published 1 month, 2 weeks ago
Description
Foghorn Therapeutics and Eli Lilly discontinue their SMARCA2 degrader program, Novartis licenses Abogen's autoimmune mRNA therapy while AstraZeneca, Daiichi Sankyo, and Summit Therapeutics team up on a breast cancer combination trial, and Corxel's Bo Liang makes the case for oral GLP-1 therapies.
Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us